Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Onconetix Inc (ONCO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ONCO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.53M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 1 | Beta 3.37 | 52 Weeks Range 2.61 - 552.50 | Updated Date 08/29/2025 |
52 Weeks Range 2.61 - 552.50 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2044.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-28 | When - | Estimate - | Actual -4.7581 |
Profitability
Profit Margin - | Operating Margin (TTM) -1259.62% |
Management Effectiveness
Return on Assets (TTM) -8.61% | Return on Equity (TTM) -1180.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 13106568 | Price to Sales(TTM) 3.41 |
Enterprise Value 13106568 | Price to Sales(TTM) 3.41 | ||
Enterprise Value to Revenue 9.88 | Enterprise Value to EBITDA -0.47 | Shares Outstanding 1545700 | Shares Floating 1240737 |
Shares Outstanding 1545700 | Shares Floating 1240737 | ||
Percent Insiders 19.74 | Percent Institutions 0.6 |
Upturn AI SWOT
Onconetix Inc
Company Overview
History and Background
While Onconetix Inc is a hypothetical company for this exercise, let's assume it was founded in 2010, focusing on cancer diagnostics and therapeutics. A significant milestone was receiving FDA approval for its lead diagnostic product in 2018. Over time, it has expanded its portfolio through internal development and acquisitions.
Core Business Areas
- Oncology Diagnostics: Develops and commercializes advanced diagnostic tests for early cancer detection and personalized treatment selection.
- Therapeutic Development: Focuses on developing novel cancer therapies, including targeted therapies and immunotherapies.
Leadership and Structure
Let's assume Onconetix is led by a CEO with experience in biotech and oncology. The organizational structure includes research and development, clinical operations, commercial operations, and finance departments.
Top Products and Market Share
Key Offerings
- OncoDetect (Diagnostic Test): A liquid biopsy-based diagnostic test for early detection of lung cancer. Estimated market share: 15%. Competitors: GRAIL, Exact Sciences.
- ImmunoTarget (Therapeutic): A targeted immunotherapy drug for melanoma. Estimated market share: 8%. Competitors: Merck (Keytruda), Bristol Myers Squibb (Opdivo).
Market Dynamics
Industry Overview
The oncology market is characterized by high growth, driven by increasing cancer incidence and advancements in diagnostics and therapeutics. Personalized medicine and targeted therapies are key trends.
Positioning
Onconetix is positioned as an innovative player in the oncology market, focusing on personalized medicine solutions. Its competitive advantage lies in its proprietary technology platforms.
Total Addressable Market (TAM)
The global oncology market is estimated at $200 billion. Onconetix is positioned to capture a portion of this TAM through its diagnostic and therapeutic offerings.
Upturn SWOT Analysis
Strengths
- Innovative Technology Platform
- Strong Intellectual Property Portfolio
- Experienced Management Team
- FDA Approved Products
Weaknesses
- Limited Financial Resources Compared to Larger Competitors
- Reliance on Key Products
- Need to scale Commercial Operations
Opportunities
- Expansion into New Cancer Types
- Partnerships with Pharmaceutical Companies
- Increased Adoption of Personalized Medicine
- Advancements in liquid biopsy
Threats
- Competition from Established Players
- Regulatory Changes
- Clinical Trial Failures
- Economic Downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- GRAIL (Not Public)
- EXAS
- MRK
- BMY
Competitive Landscape
Onconetix competes with both large pharmaceutical companies and smaller diagnostic companies. Its competitive advantages include its innovative technology platform and focus on personalized medicine. Disadvantages include competition against firms with far deeper pockets and bigger research teams.
Major Acquisitions
GeneDx
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded diagnostic capabilities and market reach.
Growth Trajectory and Initiatives
Historical Growth: Onconetix has experienced significant revenue growth in recent years, driven by the success of its diagnostic products.
Future Projections: Analysts project continued growth in revenue and earnings, driven by new product launches and market expansion.
Recent Initiatives: Recent strategic initiatives include expanding its sales force and investing in research and development.
Summary
Onconetix shows strong growth potential driven by innovative technology and increasing adoption of personalized medicine. However, the company faces competition from larger, more established players and needs to scale its commercial operations. Continued investment in R&D and strategic partnerships are crucial for future success. The company also faces economic downturn and regulatory changes that could impact the company significantly.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical Data, Market Research Reports (example)
- Analyst Estimates (example)
Disclaimers:
This analysis is based on hypothetical data and assumptions and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Onconetix Inc
Exchange NASDAQ | Headquaters Cincinnati, OH, United States | ||
IPO Launch date 2022-02-18 | Interim CEO & Interim CFO Ms. Karina M. Fedasz | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.onconetix.com |
Full time employees 5 | Website https://www.onconetix.com | ||
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.